The Future of Intelligent Intervention
Patent Portfolio
Minimally Invasive AI Assisted Robotic Fusion Biopsy.
National patent applications with amended and improved claims have been filed in the United Kingdom, Türkiye, and Qatar.
clinical evidence
Akdeniz University Ethical Approval • KOSGEB-Supported R&D
Submitted to the Journal of Vascular and Interventional Radiology (JVIR)
-
50 Completed Cases.
-
Validated by a 48-patient prospective study demonstrating 91.7% detection in PI-RADS 5 lesions and mean tumour involvement of 68.5% in robotic cores versus 31.4% in systematic cores (p<0.01).
-
47.9% cancer detection rate demonstrated through a 48-patient prospective study.
-
8.7% of cancers detected exclusively by the robotic system — missed entirely by standard systematic biopsy.
For Patients
Specialist AI-assisted robotic fusion biopsy and minimally invasive interventional radiology. 91.7% detection in high-risk lesions. Clinically precise.
For Partners
A clinically validated AI/ML platform with patent-protected technology. Exploring selective collaboration with advanced imaging and diagnostic technology groups.
For Investors
Prospective clinical data. Multi-jurisdictional IP. Government-backed funding signals across key markets.
Beyond Robotics. Clinical Intelligence.
DrSystems Tech Ltd is an AI/ML clinical intelligence platform for interventional radiology — not a technology company searching for a clinical application, but a clinical practice that built an intelligent system from real-world outcomes.
Founded by Prof. Dr. Aykut Recep Aktaş, a practising interventional radiology specialist, and structured for international scale by Idris Khan, the platform represents a new category: clinically grounded intelligence infrastructure.
The AI/ML engine learns from every procedure — building a compounding clinical data asset.
91.7%
PI-RADS 5 Detection Rate
Leadership Team
DrSystems Tech Ltd is directed by a core leadership team comprising clinical, technical, and commercial experts.
Prof. Dr. Aykut Recep Aktaş
Interventional Radiology Specialist. Medical Lead & Co-Founder.
Prof. Dr. Aykut Recep Aktaş is a specialist in interventional radiology with a dedicated clinical focus on minimally invasive, AI-assisted robotic fusion biopsy. He has developed a 7-DOF robotic biopsy system with 3-point volumetric co-registration that has produced a 48-patient prospective dataset demonstrating a 47.9% cancer detection rate, 91.7% detection in PI-RADS 5 lesions, and mean tumour involvement of 68.5% in robotic cores versus 31.4% in systematic (p<0.01). Results have been submitted to the Journal of Vascular and Interventional Radiology. This research was conducted under ethical approval from Akdeniz University Technopark and funded by KOSGEB, the Turkish government’s SME development agency. His broader clinical practice covers vascular and venous procedures, prostate interventions, embolisation, nodule assessment, and oncological applications. He practises at Memorial Antalya Hospital and holds a private clinic in Antalya, Türkiye. Clinical training programmes building on his experience in physician education are in development.
Idris Khan
CHIEF EXECUTIVE OFFICER
Idris Khan is the commercial architect behind DrSystems Tech Ltd. His background spans international expansion, strategic alliance development, and the deployment of advanced tactical intelligence and covert communications systems across multiple jurisdictions. He brings deep-tech and security sector experience, cross-border commercial structuring capability, and multi-jurisdictional IP and corporate strategy to the platform. His role at DrSystems Tech is entirely non-clinical. He is responsible for the platform’s corporate structure, IP commercialisation strategy, market positioning, and growth architecture across the UK, Türkiye, and the GCC region.
Aynur Aktaş
Chief Financial Officer
Financial strategy and governance.
Atakan Aktaş
Clinical Operations
Multi-site clinical execution.
Buğra Musa Ayvali
AI & Software Engineering Lead
Architect of the AI/ML engine.